Symbol | Exchange | Currency |
|---|
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022. Business...
Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE...
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received approval from the human research ethics committee (HREC) to kick off its Phase I/II clinical trial assessing RECCE®...
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan....
COSTA MESA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Spectrum Group International, Inc. (SPGZ) (“SGI” or the “Company”), an integrated network of leading companies concentrating...
NEW YORK and KUALA LUMPUR, Malaysia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Treasure Global Inc (NASDAQ: TGL) (“TGI” or the “Company”), an innovative e-commerce platform providing...
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.
| Average | 3.100 (+264.706% Upside) |
| High | 4.000 |
| Low | 1.000 |
| Price | 0.850 |
| No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 23.60 | 23.93 | 23.54 | -0.120 | -0.51% | 6.13M | Sydney | |||
| 2.04 | 2.07 | 2.04 | +0.010 | +0.49% | 3.22M | Sydney | |||
| 66.47 | 67.96 | 66.47 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.036 | 0.037 | 0.036 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.39 | 0.39 | 0.37 | +0.010 | +2.63% | 6.18K | Sydney | |||
| 4.77 | 4.94 | 4.76 | +0.020 | +0.42% | 18.69M | Sydney | |||
| 18.90 | 18.90 | 18.60 | +0.34 | +1.80% | 1.94K | Sydney | |||
| 0.81 | 0.82 | 0.80 | +0.005 | +0.62% | 166.24K | Sydney | |||
| 0.088 | 0.093 | 0.087 | +0.001 | +1.15% | 1.25M | Sydney | |||
| 13.67 | 13.85 | 13.62 | -0.26 | -1.87% | 13.83K | Sydney | |||
| 1.68 | 1.695 | 1.555 | +0.080 | +5.00% | 629.45K | Sydney | |||
| 7.04 | 7.20 | 7.01 | -0.070 | -0.98% | 10.70M | Sydney | |||
| 2.38 | 2.40 | 2.35 | +0.020 | +0.85% | 56.43K | Sydney | |||
| 0.255 | 0.275 | 0.255 | -0.015 | -5.56% | 124.72K | Sydney | |||
| 4.27 | 4.29 | 4.22 | 0.00 | 0.00% | 0.00 | Sydney |